Literature DB >> 30293250

Ex vivo indocyanine green fluorescence imaging for the detection of lymph node involvement in advanced-stage ovarian cancer.

Catalin-Florin Pop1, Isabelle Veys1, Maria Gomez Galdon2, Michel Moreau3, Denis Larsimont2, Vincent Donckier1, Pierre Bourgeois4, Gabriel Liberale1.   

Abstract

BACKGROUND AND OBJECTIVES: The aim of this study was to evaluate the role of indocyanine green (ICG) fluorescence imaging (FI) for the ex vivo detection of metastatic lymph nodes (LNs) in advanced stage ovarian cancer (AOC).
METHODS: Paraffin-embedded LNs from patients included in a previous ICG-FI study (Protocol NCT01834469) were further assessed for fluorescence. Intravenous injection of ICG was delivered intraoperatively. Tumor-to-background ratios (TBRs) were calculated.
RESULTS: A total of 675 LNs from 19 patients were analyzed. The mean LN number per patient was 29.3 (median: 24; range 2-77). Seventy-three LNs were malignant (10.8%), 602 were benign (89.2%). The mean TBR of all LNs was 1.5 (SD 0.8). With a cut-off TBR of 1.3, the sensitivity, specificity, positive predictive, and negative predictive values of ICG-FI for retroperitoneal LNs were 80%, 41%, 2.8%, and 99%, respectively. On univariate analysis, only the fluorescence ratio (TBR ≥ 1.3) was correlated with malignancy at pathology (P = 0.03). No predictive factors of pathological LN status were found on multivariate analysis.
CONCLUSIONS: Ex vivo ICG-FI of retroperitoneal LNs in AOC had good sensitivity but poor specificity. However, its high negative predictive value could make it an appropriate complementary tool to focus pathological analysis on fluorescent LNs.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  fluorescence imaging (FI); indocyanine green (ICG); ovarian cancer (OC); sentinel lymph node (SLN)

Mesh:

Substances:

Year:  2018        PMID: 30293250     DOI: 10.1002/jso.25263

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  6 in total

Review 1.  Intraoperative imaging in pathology-assisted surgery.

Authors:  Floris J Voskuil; Jasper Vonk; Bert van der Vegt; Schelto Kruijff; Vasilis Ntziachristos; Pieter J van der Zaag; Max J H Witjes; Gooitzen M van Dam
Journal:  Nat Biomed Eng       Date:  2021-11-08       Impact factor: 25.671

2.  Near-Infrared Fluorescence Axillary Reverse Mapping (ARM) Procedure in Invasive Breast Cancer: Relationship between Fluorescence Signal in ARM Lymph Nodes and Clinical Outcomes.

Authors:  Muriel Abbaci; Angelica Conversano; Maryam Karimi; Marie-Christine Mathieu; Valérie Rouffiac; Frederic De Leeuw; Stefan Michiels; Corinne Laplace-Builhé; Chafika Mazouni
Journal:  Cancers (Basel)       Date:  2022-05-25       Impact factor: 6.575

3.  Optical molecular imaging can differentiate metastatic from benign lymph nodes in head and neck cancer.

Authors:  Naoki Nishio; Nynke S van den Berg; Stan van Keulen; Brock A Martin; Shayan Fakurnejad; Nutte Teraphongphom; Stefania U Chirita; Nicholas J Oberhelman; Guolan Lu; Crista E Horton; Michael J Kaplan; Vasu Divi; A Dimitrios Colevas; Eben L Rosenthal
Journal:  Nat Commun       Date:  2019-11-06       Impact factor: 14.919

4.  Near-Infrared Fluorescence Imaging of Breast Cancer and Axillary Lymph Nodes After Intravenous Injection of Free Indocyanine Green.

Authors:  Pierre Bourgeois; Isabelle Veys; Danielle Noterman; Filip De Neubourg; Marie Chintinne; Sophie Vankerckhove; Jean-Marie Nogaret
Journal:  Front Oncol       Date:  2021-03-09       Impact factor: 6.244

Review 5.  Sentinel Lymph Node Mapping: Current Applications and Future Perspectives in Gynecology Malignant Tumors.

Authors:  Tianyou Wang; Yan Xu; Wenyu Shao; Chao Wang
Journal:  Front Med (Lausanne)       Date:  2022-06-29

6.  Hyperspectral Imaging for Tissue Classification after Advanced Stage Ovarian Cancer Surgery-A Pilot Study.

Authors:  Sharline M van Vliet-Pérez; Nick J van de Berg; Francesca Manni; Marco Lai; Lucia Rijstenberg; Benno H W Hendriks; Jenny Dankelman; Patricia C Ewing-Graham; Gatske M Nieuwenhuyzen-de Boer; Heleen J van Beekhuizen
Journal:  Cancers (Basel)       Date:  2022-03-10       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.